| Patents for A61P 27 - Drugs for disorders of the senses (53,017) |
|---|
| 02/06/2003 | WO2003009866A1 Use of the disintegrin domain of an adamalysin as anti-angiogenic, anti-invasive and anti-metastatic agent |
| 02/06/2003 | WO2003009843A1 Use of thiazole derivatives for preparing a medicine for protecting mitochondria |
| 02/06/2003 | WO2003009842A1 Injectable galenic formulation for use in a diagnosis or a photodynamic therapy and method for preparing same |
| 02/06/2003 | WO2003009807A2 Cytoprotective compounds, pharmaceutical and cosmetic formulations, and methods |
| 02/06/2003 | WO2003009802A2 Synergistic antimicrobial ophthalmic and dermatologic preparations containing chlorite and hydrogen peroxide |
| 02/06/2003 | WO2003009783A1 Laminates for treating cornea and process for producing the same |
| 02/06/2003 | WO2002079146A3 Compounds useful as modulators of melanocortin receptors and pharmaceutical compositions comprising same |
| 02/06/2003 | WO2002067851A3 Method for treating fibrotic diseases or other indications iiic |
| 02/06/2003 | WO2002061110A3 Nucleic acid derivatives |
| 02/06/2003 | WO2002048134A3 Di-substituted aminomethyl chroman derivative beta-3 adrenoreceptor agonists |
| 02/06/2003 | WO2002039953A3 Texaphyrin coordination compounds and uses thereof |
| 02/06/2003 | WO2002010137A9 Indazole derivatives as jnk inhibitors |
| 02/06/2003 | WO2000050040A8 Method and composition for prevention of scar formation in glaucoma filtration bleb and drainage fistula |
| 02/06/2003 | US20030028026 Nitrate salts of Salbutamol, Cetirizine, Loratadine, Terfenadine, Emedastine, Ketotifen, Nedocromil, Ambroxol, Dextromethorphan, Dextorphan, Isoniazide, Erythromycin, and Pyrazinamide; respiratory system pathology treatment |
| 02/06/2003 | US20030028008 Nucleotide sequences coding polypeptide for use in the treatment of urogenital, tumor, antherosclerotic and kidney disorders |
| 02/06/2003 | US20030027999 143 human secreted proteins |
| 02/06/2003 | US20030027983 Transport protein for use in the treatment of blood, hypertensive and epileptic disorders |
| 02/06/2003 | US20030027867 Use of R-NSAID compounds for anti-HIV treatment |
| 02/06/2003 | US20030027851 Readily soluble crystal modification; specific X-ray diffraction pattern obtained with a focusing Debye-Scherrer beam and Cu-K alpha 1-radiation |
| 02/06/2003 | US20030027846 Cyclopentane heptan(ene) acyl sulfonamide, 2-alkyl or 2-arylalkyl, or 2-heteroarylalkenyl derivatives as therapeutic agents |
| 02/06/2003 | US20030027820 Method for treating fibrotic diseases or other indications V |
| 02/06/2003 | US20030027811 Compositions containing alpha-2-adrenergic agonist components |
| 02/06/2003 | US20030027807 Vitronectin receptor antagonists, their preparation and their use |
| 02/06/2003 | US20030027804 Administering to the mammal a menopause disorder effective amount of an orally deliverable pharmaceutically- acceptable sex hormone binding globulin synthesis inhibiting agent, and at least one of a non-orally deliverable steroids |
| 02/06/2003 | US20030027801 Administering substitued guanidine compounds for therapy of decreased blood flow or nutrient supply to retinal tissue or optic nerve, or retinal ischemia or trauma, or optic nerve injury |
| 02/06/2003 | US20030027752 Leucine-based motif and clostridial neurotoxins |
| 02/06/2003 | US20030027745 Assessing first value of indicator factor inmammals which is correlated to ocular oxidative stress and inflammation; assessing a second value of the at least one indicator; comparing values for measuing ocular oxidative stress |
| 02/06/2003 | US20030027744 Use of a CD40:CD154 binding interruptor to treat immunological complications of the eye |
| 02/06/2003 | US20030027297 19 human secreted proteins |
| 02/06/2003 | US20030027158 Novel nucleic acid sequences encoding human breast tumor-associated protein 47-like polypeptides |
| 02/06/2003 | US20030026862 (+)-Cycloolivil as antioxidant obtained from a new natural source namely stereospermum personatum |
| 02/06/2003 | CA2857312A1 Nucleic acids, polypeptides, and methods for modulating apoptosis using deoxyhypusine synthase (dhs) |
| 02/06/2003 | CA2454822A1 Nucleic acids, polypeptides, and methods for modulating apoptosis using apoptosis-specific eif-5a |
| 02/06/2003 | CA2454150A1 Injectable galenic formulation for use in a diagnosis or a photodynamic therapy and method for preparing same |
| 02/06/2003 | CA2453561A1 Use of the disintegrin domain of an adamalysin as anti-angiogenic, anti-invasive and anti-metastatic agent |
| 02/06/2003 | CA2452259A1 Arylsulfonamide derivatives as c-jun-n-terminal kinases (jnk's) inhibitors |
| 02/06/2003 | CA2452159A1 Cytoprotective compounds, pharmaceutical and cosmetic formulations, and methods |
| 02/05/2003 | WO2002014280A1 Piperidine derivatives and drugs containing these derivatives as the active ingredient |
| 02/05/2003 | EP1281401A2 The medical effect of Jojoba oil |
| 02/05/2003 | EP1280929A2 Vectors for ocular transduction and use thereof for genetic therapy |
| 02/05/2003 | EP1280908A2 Treatment of neoplasia / transformation using pituitary tumor transforming gene 2 |
| 02/05/2003 | EP1280907A2 Method of modulating activation of lymphocytes via modulation of pituitary tumor transforming gene, related screeining methods |
| 02/05/2003 | EP1280906A2 Methods of modulating angiogenesis by regulating the expression of pituitary tumor transforming gene (pttg) |
| 02/05/2003 | EP1280820A2 Anti-inflammatory compounds and uses thereof |
| 02/05/2003 | EP1280815A1 29 human secreted proteins |
| 02/05/2003 | EP1280799A1 Ortho-substituted anthranilic acid amides and their use as medicaments |
| 02/05/2003 | EP1280798A1 Bicyclic heterocylces, medicaments containing said compounds, the use thereof and method for producing them |
| 02/05/2003 | EP1280785A1 Phenylsulphonylpiperazinyl derivatives as 5-ht receptor ligands |
| 02/05/2003 | EP1280781A1 5-ht 7 receptor antagonists |
| 02/05/2003 | EP1280776A1 Substituted benzoic acid amides and use thereof for the inhibition of angiogenesis |
| 02/05/2003 | EP1280546A1 Method and composition for the treatment of angiogenesis |
| 02/05/2003 | EP1280536A2 Method for treating retinal degeneration with purinergic receptor agonists |
| 02/05/2003 | EP1280528A2 R-eliprodil for treating glaucoma |
| 02/05/2003 | EP1280525A2 Methods and compositions for modulating alpha adrenergic receptor activity |
| 02/05/2003 | EP1280524A2 Methods and compositions for modulating alpha adrenergic receptor activity |
| 02/05/2003 | EP1280523A2 Use of benzamide derivatives for the treatment of high ocular tension and glaucoma |
| 02/05/2003 | EP1280515A2 Pharmaceutical compositions comprising cannabis |
| 02/05/2003 | EP1194145B1 Stable xylometazoline and oxymetazoline solution |
| 02/05/2003 | EP1117653B1 Quinoline and quinazoline derivatives and their use as inhibitors of cytokine mediated diseases |
| 02/05/2003 | CN1395581A Recombinant antibodies to human IL-1 beta |
| 02/05/2003 | CN1395569A Oxazolidinone thioamides with piperazine amide substituents |
| 02/05/2003 | CN1395563A Isatine derivatives with neurotrophic activity |
| 02/05/2003 | CN1395489A Physiologically balanced ionized acidic solution and methodology for use in wound healing |
| 02/05/2003 | CN1394855A Substituted heterocyclic compound |
| 02/05/2003 | CN1394624A Chinese medicine prescription for curing eye disease and its preparation method |
| 02/05/2003 | CN1394610A Herapin calcium eye drops |
| 02/05/2003 | CN1100748C Inhibition of matrix metalloproteases by 2-substituted-4-(4-substituted phenyl)-4-oxobutyric acids |
| 02/04/2003 | WO2002011734A1 Aqueous pharmaceutical compositions |
| 02/04/2003 | US6515117 C-aryl glucoside SGLT2 inhibitors and method |
| 02/04/2003 | US6515105 Vascular Endothelial Growth Factor binding to extracellular domain of NP-1 (Neuropilin-1); bioactive complexes; mediate useful cell responses or antagonize undesired biological activities; angiogenesis; cell differentiation |
| 02/04/2003 | US6515025 Use of ethynyl alanine amino diol compounds to inhibit enzymatic conversion of angiotensinogen to angiotensin I |
| 02/04/2003 | US6515021 The compounds according to the invention have pronounced activity in the fields of cell differentiation and cell proliferation |
| 02/04/2003 | US6514964 Treating diseases, conditions or disorders mediated by integrin receptors, such as vitronectin and fibronectin receptors |
| 02/04/2003 | US6514960 Use of bismuth subgallate in inhibition of production of nitric oxide synthase |
| 02/04/2003 | US6514945 Azalide antibiotic compositions |
| 02/04/2003 | US6514934 For treating sexual dysfunctions in males and females |
| 02/04/2003 | CA2421787A1 Aqueous pharmaceutical compositions |
| 02/04/2003 | CA2271478C Tissue specific expression of retinoblastoma protein |
| 01/30/2003 | WO2003008457A2 Polysaccharidic esters of retinoic acid |
| 01/30/2003 | WO2003008444A2 Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells |
| 01/30/2003 | WO2003008443A2 Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells |
| 01/30/2003 | WO2003008425A1 Novel bisphosphonate derivatives, their preparation methods and uses |
| 01/30/2003 | WO2003008409A1 Quinoline derivatives and their use as tyrosine kinase inhibitors |
| 01/30/2003 | WO2003008407A2 Phenylsulfonyl-1,3-dihydro-2h-indole-2-one derivatives, their preparation and their therapeutic use |
| 01/30/2003 | WO2003008399A1 Synthesis of udp-glucose: n-acylsphingosine glucosyltransferase inhibitors |
| 01/30/2003 | WO2003008396A1 Optically active oxazine derivative |
| 01/30/2003 | WO2003008388A1 I-form crystal of n-{2-chloro-4-[(6,7-dimethoxy-4-quinazolinyl)oxy]phenyl}-n'-propylurea and process for producing the same |
| 01/30/2003 | WO2003008377A1 Prostaglandin analogues_as ep4 receptor agonists |
| 01/30/2003 | WO2003008371A1 Substituted 4-aminocyclohexanol derivatives |
| 01/30/2003 | WO2003008370A1 Substituted 4-aminocyclohexanols |
| 01/30/2003 | WO2003008368A1 Process and intermediates to prepare latanoprost |
| 01/30/2003 | WO2003007969A1 Bio-compatible molecules for improving vision |
| 01/30/2003 | WO2003007961A1 Methods for treating neoplastic, angiogenic, fibroplastic, and/or immunosuppresive ocular irregularities via administration of methotrexate based medicaments, and ocular iontophoretic devices for delivering methotrexate based medicaments |
| 01/30/2003 | WO2003007958A1 Tetrahydroquinoxalines acting as bradykinin antagonists |
| 01/30/2003 | WO2003007954A2 Sulfonyl aryl hydroxamates and their use as matrix metalloprotease inhibitors |
| 01/30/2003 | WO2003007944A1 Treatment of macular edema with photodynamic therapy |
| 01/30/2003 | WO2003007930A2 Use of sulfonyl aryl or heteroaryl hydroxamic acids and derivatives thereof as aggrecanase inhibitors |
| 01/30/2003 | WO2003007889A2 Therapeutic agents comprising pro-apoptotic proteins |
| 01/30/2003 | WO2003007798A2 Ophthalmic use of 5 fluorourcil |
| 01/30/2003 | WO2003007689A2 Compositions and methods for use of bioactive agents derived from sulfated and sulfonated amino acids |